ADORA3 and breast cancer: The ENTPD1/NT5E/ADORA3 expression signature was not correlated with either outcome in ER–, HER2-enriched, or basal breast cancers, which do not share the same metastatic behavior (Supplementary Figure 3A), nor were signatures combining expression of the ectonucleotidases with any of the other aADO receptors in ER+ tumors (Supplementary Figure 3B).